Bind another day: The LFA-1/ICAM-1 interaction as therapeutic target

Clinical and Applied Immunology Reviews

Volumn 6, Issue 3-4, 2006, Pages 173-189

  Zecchinon, L ^a   Fett, T ^a   Vanden Bergh, P ^a   Desmecht, D ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Binding; Disease; ICAM; LFA 1; Therapeutic

Indexed keywords

CD18 ANTIGEN[112-122]; CD18 ANTIGEN[112-137]; CELL ADHESION MOLECULE; CYCLOSPORIN A; EFALIZUMAB; HU 1124; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; INTERCELLULAR ADHESION MOLECULE[1-10]; INTERCELLULAR ADHESION MOLECULE[1-21]; INTERCELLULAR ADHESION MOLECULE[12-21]; INTERCELLULAR ADHESION MOLECULE[26-50]; INTERCELLULAR ADHESION MOLECULE[6-15]; LYMPHOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 ANTAGONIST; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[237-246]; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[237-261]; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[244-253]; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[251-261]; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[441-450]; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1[441-465]; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; PROTEIN ANTIBODY; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CHILL; DRUG DOSE REGIMEN; DRUG FEVER; GENETIC DISORDER; HEADACHE; HUMAN; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; LOW DRUG DOSE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 33845403627     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cair.2006.09.004     Document Type: Article

References (102)

1. Springer T.A. Adhesion receptors of the immune system. Nature 346 (1990) 425-434
2. Hauck C.R. Cell adhesion receptors-signaling capacity and exploitation by bacterial pathogens. Med Microbiol Immunol 191 (2002) 55-62
3. Hogg N., Smith A., McDowall A., Giles K., Stanley P., Laschinger M., et al. How T cells use LFA-1 to attach and migrate. Immunol Lett 92 (2004) 51-54
4. Springer T.A., Dustin M.L., Kishimoto T.K., and Marlin S.D. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 5 (1987) 223-252
5. Cabanas C., and Sanchez-Madrid F. CD11a (leukocyte integrin LFA-1 alpha subunit). J Biol Regul Homeost Agents 13 (1999) 126-129
6. Sanchez-Madrid F., Nagy J.A., Robbins E., Simon P., and Springer T.A. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150, 95 molecule. J Exp Med 158 (1983) 1785-1803
7. Carman C.V., and Springer T.A. Integrin avidity regulation: are changes in affinity and conformation underemphasized?. Curr Opin Cell Biol 15 (2003) 547-556
8. Springer T.A., and Wang J.H. The three-dimensional structure of integrins and their ligands, and conformational regulation of cell adhesion. Adv Protein Chem 68 (2004) 29-63
9. Takagi J., Petre B.M., Walz T., and Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110 (2002) 599-611
10. Takagi J., and Springer T.A. Integrin activation and structural rearrangement. Immunol Rev 186 (2002) 141-163
11. Kim M., Carman C.V., Yang W., Salas A., and Springer T.A. The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J Cell Biol 167 (2004) 1241-1253
12. Stewart M.P., McDowall A., and Hogg N. LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J Cell Biol 140 (1998) 699-707
13. Lub M., van Kooyk Y., van Vliet S.J., and Figdor C.G. Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1. Mol Biol Cell 8 (1997) 341-351
14. Rothlein R., Dustin M.L., Marlin S.D., and Springer T.A. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137 (1986) 1270-1274
15. Staunton D.E., Marlin S.D., Stratowa C., Dustin M.L., and Springer T.A. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52 (1988) 925-933
16. Hersmann G.H., Kriegsmann J., Simon J., Huttich C., and Brauer R. Expression of cell adhesion molecules and cytokines in murine antigen-induced arthritis. Cell Adhes Commun 6 (1998) 69-82
17. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., and Springer T.A. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137 (1986) 245-254
18. Staunton D.E., Dustin M.L., Erickson H.P., and Springer T.A. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 61 (1990) 243-254
19. Bella J., Kolatkar P.R., Marlor C.W., Greve J.M., and Rossmann M.G. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc Natl Acad Sci USA 95 (1998) 4140-4145
20. Dustin M.L., Carpen O., and Springer T.A. Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J Immunol 148 (1992) 2654-2663
21. Casasnovas J.M., Stehle T., Liu J.H., Wang J.H., and Springer T.A. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc Natl Acad Sci USA 95 (1998) 4134-4139
22. Hermand P., Huet M., Callebaut I., Gane P., Ihanus E., Gahmberg C.G., et al. Binding sites of leukocyte beta 2 integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein. J Biol Chem 275 (2000) 26002-26010
23. Diamond M.S., Staunton D.E., Marlin S.D., and Springer T.A. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65 (1991) 961-971
24. Miller J., Knorr R., Ferrone M., Houdei R., Carron C.P., and Dustin M.L. Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function associated-1. J Exp Med 182 (1995) 1231-1241
25. Jun C.D., Shimaoka M., Carman C.V., Takagi J., and Springer T.A. Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion. Proc Natl Acad Sci USA 98 (2001) 6830-6835
26. Jun C.D., Carman C.V., Redick S.D., Shimaoka M., Erickson H.P., and Springer T.A. Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 276 (2001) 29019-29027
27. Casasnovas J.M., Pieroni C., and Springer T.A. Lymphocyte function-associated antigen-1 binding residues in intercellular adhesion molecule-2 (ICAM-2) and the integrin binding surface in the ICAM subfamily. Proc Natl Acad Sci USA 96 (1999) 3017-3022
28. Stanley P., and Hogg N. The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 but not Gln-73. J Biol Chem 273 (1998) 3358-3362
29. Fisher K.L., Lu J., Riddle L., Kim K.J., Presta L.G., and Bodary S.C. Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen 1. Mol Biol Cell 8 (1997) 501-515
30. Staunton D.E., Dustin M.L., and Springer T.A. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339 (1989) 61-64
31. Gahmberg C.G., Nortamo P., Zimmermann D., and Ruoslahti E. The human leukocyte-adhesion ligand, intercellular-adhesion molecule 2. Expression and characterization of the protein. Eur J Biochem 195 (1991) 177-182
32. Dustin M.L., Garcia-Aguilar J., Hibbs M.L., Larson R.S., Stacker S.A., Staunton D.E., et al. Structure and regulation of the leukocyte adhesion receptor LFA-1 and its counterreceptors, ICAM-1 and ICAM-2. Cold Spring Harb Symp Quant Biol 54 (1989) 753-765
33. Diacovo T.G., deFougerolles A.R., Bainton D.F., and Springer T.A. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest 94 (1994) 1243-1251
34. Nortamo P., Li R., Renkonen R., Timonen T., Prieto J., Patarroyo M., et al. The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol 21 (1991) 2629-2632
35. Casasnovas J.M., Springer T.A., Liu J.H., Harrison S.C., and Wang J.H. Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Nature 387 (1997) 312-315
36. Li R., Nortamo P., Valmu L., Tolvanen M., Huuskonen J., Kantor C., et al. A peptide from ICAM-2 binds to the leukocyte integrin CD11a/CD18 and inhibits endothelial cell adhesion. J Biol Chem 268 (1993) 17513-17518
37. Fawcett J., Holness C.L., Needham L.A., Turley H., Gatter K.C., Mason D.Y., et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 360 (1992) 481-484
38. Van der Vieren M., Le Trong H., Wood C.L., Moore P.F., St John T., Staunton D.E., et al. A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3. Immunity 3 (1995) 683-690
39. de Fougerolles A.R., and Springer T.A. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 175 (1992) 185-190
40. Vazeux R., Hoffman P.A., Tomita J.K., Dickinson E.S., Jasman R.L., St John T., et al. Cloning and characterization of a new intercellular adhesion molecule ICAM-R. Nature 360 (1992) 485-488
41. Holness C.L., Bates P.A., Little A.J., Buckley C.D., McDowall A., Bossy D., et al. Analysis of the binding site on intercellular adhesion molecule 3 for the leukocyte integrin lymphocyte function-associated antigen 1. J Biol Chem 270 (1995) 877-884
42. Klickstein L.B., York M.R., Fougerolles A.R., and Springer T.A. Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1). J Biol Chem 271 (1996) 23920-23927
43. Bailly P., Hermand P., Callebaut I., Sonneborn H.H., Khamlichi S., Mornon J.P., et al. The LW blood group glycoprotein is homologous to intercellular adhesion molecules. Proc Natl Acad Sci USA 91 (1994) 5306-5310
44. Bailly P., Tontti E., Hermand P., Cartron J.P., and Gahmberg C.G. The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Eur J Immunol 25 (1995) 3316-3320
45. Bloy C., Hermand P., Blanchard D., Cherif-Zahar B., Goossens D., and Cartron J.P. Surface orientation and antigen properties of Rh and LW polypeptides of the human erythrocyte membrane. J Biol Chem 265 (1990) 21482-21487
46. Yoshihara Y., Oka S., Nemoto Y., Watanabe Y., Nagata S., Kagamiyama H., et al. An ICAM-related neuronal glycoprotein, telencephalin, with brain segment-specific expression. Neuron 12 (1994) 541-553
47. Tian L., Yoshihara Y., Mizuno T., Mori K., and Gahmberg C.G. The neuronal glycoprotein telencephalin is a cellular ligand for the CD11a/CD18 leukocyte integrin. J Immunol 158 (1997) 928-936
48. Mizuno T., Yoshihara Y., Inazawa J., Kagamiyama H., and Mori K. cDNA cloning and chromosomal localization of the human telencephalin and its distinctive interaction with lymphocyte function-associated antigen-1. J Biol Chem 272 (1997) 1156-1163
49. Tian L., Kilgannon P., Yoshihara Y., Mori K., Gallatin W.M., Carpen O., et al. Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/CD18. Eur J Immunol 30 (2000) 810-818
50. Martin-Padura I., Lostaglio S., Schneemann M., Williams L., Romano M., Fruscella P., et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 142 (1998) 117-127
51. Williams L.A., Martin-Padura I., Dejana E., Hogg N., and Simmons D.L. Identification and characterisation of human Junctional Adhesion Molecule (JAM). Mol Immunol 36 (1999) 1175-1188
52. Bazzoni G., Martinez-Estrada O.M., Orsenigo F., Cordenonsi M., Citi S., and Dejana E. Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin. J Biol Chem 275 (2000) 20520-20526
53. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15 (2003) 525-530
54. Ostermann G., Weber K.S., Zernecke A., Schroder A., and Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol 3 (2002) 151-158
55. Del Maschio A., De Luigi A., Martin-Padura I., Brockhaus M., Bartfai T., Fruscella P., et al. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J Exp Med 190 (1999) 1351-1356
56. Humphries M.J. Integrin structure. Biochem Soc Trans 28 (2000) 311-339
57. Randi A.M., and Hogg N. I domain of beta 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J Biol Chem 269 (1994) 12395-12398
58. Leitinger B., and Hogg N. Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1. Mol Biol Cell 11 (2000) 677-690
59. Huang C., and Springer T.A. A binding interface on the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biol Chem 270 (1995) 19008-19016
60. McDowall A., Leitinger B., Stanley P., Bates P.A., Randi A.M., and Hogg N. The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1). J Biol Chem 273 (1998) 27396-27403
61. Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., et al. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112 (2003) 99-111
62. Fraemohs L., Koenen R.R., Ostermann G., Heinemann B., and Weber C. The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain. J Immunol 173 (2004) 6259-6264
63. Stanley P., Bates P.A., Harvey J., Bennett R.I., and Hogg N. Integrin LFA-1 alpha subunit contains an ICAM-1 binding site in domains V and VI. EMBO J 13 (1994) 1790-1798
64. Binnerts M.E., and van Kooyk Y. How LFA-1 binds to different ligands. Immunol Today 20 (1999) 240-245
65. Papp K., Bissonnette R., Krueger J.G., Carey W., Gratton D., Gulliver W.P., et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45 (2001) 665-674
66. Pietrzak A., Podhorecka M., Chodorowska G., Rolinski J., and Urban J. Efaluzimab in the treatment of psoriasis. Ann Univ Mariae Curie Sklodowska (Med) 58 (2003) 174-178
67. Cather J.C., and Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 3 (2003) 361-370
68. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., and Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138 (2002) 591-600
69. Iwamoto I., and Nakao A. Induction of Th2 cell tolerance to a soluble antigen by blockade of the LFA-1-dependent pathway prevents allergic inflammation. Immunol Res 14 (1995) 263-270
70. Anderson M.E., and Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24 (2003) 487-501
71. Barouch F.C., Miyamoto K., Allport J.R., Fujita K., Bursell S.E., Aiello L.P., et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 41 (2000) 1153-1158
72. Moriyama H., Yokono K., Amano K., Nagata M., Hasegawa Y., Okamoto N., et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 157 (1996) 3737-3743
73. Kavanaugh A.F., Davis L.S., Jain R.I., Nichols L.A., Norris S.H., and Lipsky P.E. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 23 (1996) 1338-1344
74. Schulze-Koops H., Lipsky P.E., Kavanaugh A.F., and Davis L.S. Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 155 (1995) 5029-5037
75. Kobayashi Y., Kawai K., Honda H., Tomida S., Niimi N., Tamatani T., et al. Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. Cell Immunol 164 (1995) 295-305
76. Lenschow D.J., Ho S.C., Sattar H., Rhee L., Gray G., Nabavi N., et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181 (1995) 1145-1155
77. Yusuf-Makagiansar H., Anderson M.E., Yakovleva T.V., Murray J.S., and Siahaan T.J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22 (2002) 146-167
78. Tibbetts S.A., Chirathaworn C., Nakashima M., Jois D.S., Siahaan T.J., Chan M.A., et al. Peptides derived from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture. Transplantation 68 (1999) 685-692
79. Tibbetts S.A., Seetharama Jois D., Siahaan T.J., Benedict S.H., and Chan M.A. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides 21 (2000) 1161-1167
80. Gursoy R.N., Jois D.S., and Siahaan T.J. Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH. J Pept Res 53 (1999) 422-431
81. Gursoy R.N., and Siahaan T.J. Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells. J Pept Res 53 (1999) 414-421
82. Jois D.S., Pal D., Tibbetts S.A., Chan M.A., Benedict S.H., and Siahaan T.J. Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide. J Pept Res 49 (1997) 517-526
83. Yusuf-Makagiansar H., Makagiansar I.T., and Siahaan T.J. Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1. Inflammation 25 (2001) 203-214
84. Yusuf-Makagiansar H., Makagiansar I.T., Hu Y., and Siahaan T.J. Synergistic inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides 22 (2001) 1955-1962
85. Yusuf-Makagiansar H., and Siahaan T.J. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm Res 18 (2001) 329-335
86. Xu C.R., Yusuf-Makagiansar H., Hu Y., Jois S.D., and Siahaan T.J. Structural and ICAM-1-docking properties of a cyclic peptide from the I-domain of LFA-1: an inhibitor of ICAM-1/LFA- 1-mediated T-cell adhesion. J Biomol Struct Dyn 19 (2002) 789-799
87. Raub T.J., and Kuentzel S.L. Kinetic and morphological evidence for endocytosis of mammalian cell integrin receptors by using an anti-fibronectin receptor beta subunit monoclonal antibody. Exp Cell Res 184 (1989) 407-426
88. Ricard I., Payet M.D., and Dupuis G. VCAM-1 is internalized by a clathrin-related pathway in human endothelial cells but its alpha 4 beta 1 integrin counter-receptor remains associated with the plasma membrane in human T lymphocytes. Eur J Immunol 28 (1998) 1708-1718
89. Jois S.D., Tibbetts S.A., Chan M.A., Benedict S.H., and Siahaan T.J. A Ca2+ binding cyclic peptide derived from the alpha-subunit of LFA-1: inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion. J Pept Res 53 (1999) 18-29
90. Jois S.D., Hughes R., and Siahaan T.J. Comparison of the solution conformations of a cell-adhesive peptide LBE and its reverse sequence EBL. J Biomol Struct Dyn 17 (1999) 429-444
91. Shannon J.P., Silva M.V., Brown D.C., and Larson R.S. Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation. J Pept Res 58 (2001) 140-150
92. Poggi A., Carosio R., Spaggiari G.M., Fortis C., Tambussi G., Dell'Antonio G., et al. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J Immunol 168 (2002) 95-101
93. Zocchi M.R., Rubartelli A., Morgavi P., and Poggi A. HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. J Immunol 161 (1998) 2938-2943
94. Gadek T.R., Burdick D.J., McDowell R.S., Stanley M.S., Marsters Jr. J.C., Paris K.J., et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295 (2002) 1086-1089
95. Burdick D.J., Marsters Jr. J.C., Aliagas-Martin I., Stanley M., Beresini M., Clark K., et al. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: structure-activity relationship of the benzoyl moiety. Bioorg Med Chem Lett 14 (2004) 2055-2059
96. Burdick D.J., Paris K., Weese K., Stanley M., Beresini M., Clark K., et al. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. Bioorg Med Chem Lett 13 (2003) 1015-1018
97. Shimaoka M., and Springer T.A. Therapeutic antagonists and the conformational regulation of the beta2 integrins. Curr Top Med Chem 4 (2004) 1485-1495
98. Liu G., Huth J.R., Olejniczak E.T., Mendoza R., DeVries P., Leitza S., et al. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J Med Chem 44 (2001) 1202-1210
99. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 292 (1999) 1-9
100. Last-Barney K., Davidson W., Cardozo M., Frye L.L., Grygon C.A., Hopkins J.L., et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J Am Chem Soc 123 (2001) 5643-5650
101. Kelly T.A., Jeanfavre D.D., McNeil D.W., Woska Jr. J.R., Reilly P.L., Mainolfi E.A., et al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol 163 (1999) 5173-5177
102. Welzenbach K., Hommel U., and Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. J Biol Chem 277 (2002) 10590-10598